Prediction tool from Kaiser Permanente researchers may identify patients at risk for HIV

July 08, 2019

Oakland, Calif. -- Researchers have developed a new analytical tool that identifies people at risk of contracting HIV so they may be referred for preventive medication. A study describing the tool was published July 5, 2019, in The Lancet HIV by investigators at Kaiser Permanente San Francisco, the Kaiser Permanente Division of Research, Beth Israel Deaconess Medical Center, and Harvard Medical School.

Looking at medical records of 3.7 million Kaiser Permanente patients, researchers developed a machine-learning algorithm to predict who would become infected with HIV during a 3-year period. The algorithm flagged 2.2% of all patients as high or very high risk; this group included nearly half the men who later became infected, a significant improvement from other published HIV risk prediction tools.

"In preexposure prophylaxis, or PrEP, we have an incredibly powerful tool to stop HIV transmission," said senior author Jonathan Volk, MD, MPH, an infectious disease physician who treats patients with HIV at Kaiser Permanente San Francisco Medical Center. PrEP is a daily antiretroviral pill that is more than 99% effective in preventing HIV.

"It is critical that we identify our patients at risk of HIV acquisition," Dr. Volk said. "We used our electronic medical record to develop a tool that could be implemented in a busy clinical practice to help providers identify patients who may benefit most from PrEP."

The Centers for Disease Control and Prevention estimates that just 7% of the people who could benefit from PrEP are taking it. Health care providers have difficulty identifying people at risk for HIV acquisition. Relying on the CDC's indications for PrEP -- sexual orientation and a history of sexually transmitted infections -- underestimates risk for some populations, including African Americans, who have relatively high HIV incidence and low PrEP use.

Finding a reliable and automated approach to predict which patients are at risk of HIV infection is a high priority for public health officials. The U.S. Preventive Services Task Force recently gave PrEP therapy its highest, grade A rating and urged researchers to develop tools to identify individuals at risk for HIV.

"Our predictive model directly addresses this gap and may be substantially more effective than current efforts to identify those who may be good PrEP candidates," Dr. Volk said. He emphasized that it does not replace the clinical judgment of medical providers but could save them time and address misconceptions about HIV risk.

The accuracy of the tool is possible because of Kaiser Permanente Northern California's comprehensive electronic health records, which track many demographic and clinical data points for its members. "Development of the tool required a setting like KP Northern California that had high-quality individual-level data on enough people to identify new HIV infections, which are rare events," explained Michael Silverberg, PhD, MPH, from the Kaiser Permanente Division of Research and co-author of the paper.

The investigators analyzed 81 variables in the electronic health record, finding 44 of them most relevant for predicting HIV risk. A tool that used these 44 variables identified 2.2% of the population as having a high or very high risk of HIV infection within 3 years. This high-risk group included 38.6% of all new HIV infections (46.4% or 32 of 69 men who were diagnosed with HIV during the study period but none of the 14 women).

The tool is limited, as are others, in identifying women at risk of contracting HIV. That's because risk for females may be dependent on the risk factors of their partners, which are not captured by the variables included in the tool, Dr. Volk explained. The tool also performs less well among patients for whom the electronic health record contains less data (because they are new enrollees or access care less frequently).

The authors compared their new tool with simpler models and found it identified more patients who acquired HIV. Importantly, simpler algorithms were less likely to identify African Americans who became infected, whereas the new tool performed well for both white and African American patients.

While access to a wide variety of patient information is an advantage for Kaiser Permanente, other health care organizations could build similar algorithms using fewer electronic health record variables, Dr. Volk said. The study found simpler models that included only 6 variables still helped identify patients at risk for HIV.

The tool could be incorporated in electronic health record systems to alert primary care providers to speak with patients most likely to benefit from discussions about PrEP. Clinicians could also take this opportunity to explain the availability of drug manufacturer and publicly funded programs that may cover all or part of the drug's copay cost. The risk thresholds established in this study flagged a small proportion (2.2%) but large number (13,463) of patients over a 3-year period as potential candidates for PrEP based on HIV risk. The study's authors note that there are no established HIV-risk thresholds for determining PrEP candidacy, and that few of the patients flagged as high risk in this study received PrEP during the study period.

"Embedding our algorithm in the electronic health record could support providers in discussing sexual health and HIV risk with their patients, ultimately increasing the uptake of PrEP and preventing new HIV infections," said lead author Julia L. Marcus, PhD, MPH, now at Harvard Medical School and Harvard Pilgrim Health Care Institute but formerly of the Kaiser Permanente Division of Research.
The project was supported by the Kaiser Permanente Northern California Community Benefit Research Program, the National Institute of Allergy and Infectious Diseases, and the National Institute of Mental Health.

Co-authors include Stacey Alexeeff, PhD, and Leo B. Hurley, MPH of the Kaiser Permanente Division of Research, and Douglas S. Krakower, MD, of Beth Israel Deaconess Medical Center.

About Kaiser Permanente

Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve 12.3 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health.

Kaiser Permanente

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to